Court Denies Agilent's Motion to Dismiss PerkinElmer Mass Spec Patent Suit | GenomeWeb

The first leg of Agilent's defense in the mass spec patent infringement suit leveled at it by PerkinElmer fell this month, with the US District Court for the District of Massachusetts denying the company's motion to dismiss the case.

This motion denied, the case will now likely turn on Agilent's claims that the patents PerkinElmer charges it has infringed upon are indistinguishable from other, expired patents, and therefore are not entitled to protection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.